Volution, Celsus Therapeutics deal

Celsus will merge with Volution in a stock transaction, with the newco to be named Akari Therapeutics. Celsus and Volution shareholders will own 8.32% and 91.68% of Akari, respectively. The deal is subject to Celsus shareholder approval and includes a $6 million termination fee. ...